Pfizer shows profit growth from cost cuts and steadier COVID sales
Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as it aims to show investors steadier execution and growth after large swings related to its COVID-19 vaccine.
In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...
Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...
Pfizer shares rose early Tuesday due to higher than expected demand for its COVID vaccine, but quickly sunk 2.3% after ...
Despite loud statements about leaving, the American company Pfizer continues to promote its drugs in Russia, using opaque schemes, and transfers part of the income to the Armed Forces of Ukraine.
The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...
Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...
Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...
Bristol Myers Squibb's FDA nod for Breyanzi (liso-cel) in relapsed/refractory CLL/SLL boosts its CAR T-cell portfolio, ...
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback